Literature DB >> 26597365

Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study.

Eran Sadot1, Diane L Reidy-Lagunes2, Laura H Tang3, Richard Kinh Gian Do4, Mithat Gonen5, Michael I D'Angelica1, Ronald P DeMatteo1, T Peter Kingham1, Bas Groot Koerkamp1, Brian R Untch1, Murray F Brennan1, William R Jarnagin1, Peter J Allen6.   

Abstract

OBJECTIVE: To analyze the natural history of small asymptomatic pancreatic neuroendocrine tumors (PanNET) and to present a matched comparison between groups who underwent either initial observation or resection. Management approach for small PanNET is uncertain.
METHODS: Incidentally discovered, sporadic, small (<3 cm), stage I-II PanNET were analyzed retrospectively between 1993 and 2013. Diagnosis was determined either by pathology or imaging characteristics. Intention-to-treat analysis was applied.
RESULTS: A total of 464 patients were reviewed. Observation was recommended for 104 patients (observation group), and these patients were matched to 77 patients in the resection group based on tumor size at initial imaging. The observation group was significantly older (median 63 vs. 59 years, p = 0.04) and tended towards shorter follow-up (44 vs. 57 months, p = 0.06). Within the observation group, 26 of the 104 patients (25 %) underwent subsequent tumor resection after a median observation interval of 30 months (range 7-135). At the time of last follow-up of the observation group, the median tumor size had not changed (1.2 cm, p = 0.7), and no patient had developed evidence of metastases. Within the resection group, low-grade (G1) pathology was recorded in 72 (95 %) tumors and 5 (6 %) developed a recurrence, which occurred after a median of 5.1 (range 2.9-8.1) years. No patient in either group died from disease. Death from other causes occurred in 11 of 181 (6 %) patients.
CONCLUSIONS: In this study, no patient who was initially observed developed metastases or died from disease after a median follow-up of 44 months. Observation for stable, small, incidentally discovered PanNET is reasonable in selected patients.

Entities:  

Mesh:

Year:  2015        PMID: 26597365      PMCID: PMC4798427          DOI: 10.1245/s10434-015-4986-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  29 in total

1.  Ramifications of screening for breast cancer: 1 in 4 cancers detected by mammography are pseudocancers.

Authors:  H Gilbert Welch; Lisa M Schwartz; Steven Woloshin
Journal:  BMJ       Date:  2006-03-25

2.  Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases.

Authors:  W Kimura; A Kuroda; Y Morioka
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

3.  Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas.

Authors:  Frederic Triponez; David Dosseh; Pierre Goudet; Patrick Cougard; Catherine Bauters; Arnaud Murat; Guillaume Cadiot; Patricia Niccoli-Sire; Jean-Alain Chayvialle; Alain Calender; Charles A G Proye
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

4.  Korea's thyroid-cancer "epidemic"--screening and overdiagnosis.

Authors:  Hyeong Sik Ahn; Hyun Jung Kim; H Gilbert Welch
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

5.  The MEA-I syndrome: an all or none phenomenon?

Authors:  J T Majewski; S D Wilson
Journal:  Surgery       Date:  1979-09       Impact factor: 3.982

6.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

7.  Skin biopsy rates and incidence of melanoma: population based ecological study.

Authors:  H Gilbert Welch; Steven Woloshin; Lisa M Schwartz
Journal:  BMJ       Date:  2005-08-04

8.  MEN I pancreas: a histological and immunohistochemical study.

Authors:  N W Thompson; R V Lloyd; R H Nishiyama; A I Vinik; W E Strodel; M D Allo; F E Eckhauser; G Talpos; T Mervak
Journal:  World J Surg       Date:  1984-08       Impact factor: 3.352

9.  Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans.

Authors:  D M Kendall; D E Sutherland; J S Najarian; F C Goetz; R P Robertson
Journal:  N Engl J Med       Date:  1990-03-29       Impact factor: 91.245

Review 10.  Pancreatic resection: effects on glucose metabolism.

Authors:  L A Slezak; D K Andersen
Journal:  World J Surg       Date:  2001-04-11       Impact factor: 3.352

View more
  39 in total

Review 1.  Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors.

Authors:  Sylvia L Asa; Stefano La Rosa; Olca Basturk; Volkan Adsay; Marianna Minnetti; Ashley B Grossman
Journal:  Endocr Pathol       Date:  2021-01-18       Impact factor: 3.943

2.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

Review 3.  The Surgeon's Role in Treating Chronic Pancreatitis and Incidentally Discovered Pancreatic Lesions.

Authors:  Vikrom K Dhar; Brent T Xia; Syed A Ahmad
Journal:  J Gastrointest Surg       Date:  2017-08-14       Impact factor: 3.452

Review 4.  Role of surgery in pancreatic neuroendocrine tumor.

Authors:  Kai Pun Wong; Julian Shun Tsang; Brian Hung-Hin Lang
Journal:  Gland Surg       Date:  2018-02

5.  Robotic enucleations of pancreatic benign or low-grade malignant tumors: preliminary results and comparison with robotic demolitive resections.

Authors:  Ilenia Bartolini; Lapo Bencini; Marco Bernini; Marco Farsi; Massimo Calistri; Mario Annecchiarico; Luca Moraldi; Andrea Coratti
Journal:  Surg Endosc       Date:  2018-11-12       Impact factor: 4.584

6.  Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.

Authors:  Hussein A Assi; Sarbajit Mukherjee; Pamela L Kunz; Michael Machiorlatti; Sara Vesely; Vipul Pareek; Hassan Hatoum
Journal:  Oncologist       Date:  2019-10-02

7.  Comparison of prognosis between observation and surgical resection groups with small sporadic non-functional pancreatic neuroendocrine neoplasms without distant metastasis.

Authors:  Yusuke Kurita; Kazuo Hara; Takamichi Kuwahara; Nobumasa Mizuno; Nozomi Okuno; Shin Haba; Masataka Okuno; Seiji Natsume; Yoshiki Senda; Kensuke Kubota; Atsushi Nakajima; Yasumasa Niwa; Yasuhiro Shimizu
Journal:  J Gastroenterol       Date:  2019-12-19       Impact factor: 7.527

8.  The Landmark Series: Pancreatic Neuroendocrine Tumors.

Authors:  Jordan M Cloyd; George A Poultsides
Journal:  Ann Surg Oncol       Date:  2020-09-18       Impact factor: 5.344

Review 9.  The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines.

Authors:  Wouter T Zandee; Wouter W de Herder
Journal:  Neuroendocrinology       Date:  2018-01-10       Impact factor: 4.914

Review 10.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.